Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
372 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05641324 | A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) | terminated | Phase 1 | 4 | Anaveon AGINDUSTRY | 5 | Feb 12, 2024 | clinicaltrials |
| NCT03838042 | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | recruiting | Phase 1 / Phase 2 | 91 | University Hospital HeidelbergOTHER | 7 | Feb 7, 2024 | clinicaltrials |
| NCT02829723 | A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 192 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 18, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | terminated | Phase 1 | 14 | IpsenINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT02608268 | Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 252 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 6, 2023 | clinicaltrials |
| NCT03409458 | A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab(PAVE-1) | completed | Phase 1 / Phase 2 | 68 | Promontory Therapeutics Inc.INDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT03555149 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | terminated | Phase 1 / Phase 2 | 96 | Hoffmann-La RocheINDUSTRY | 5 | Nov 7, 2023 | clinicaltrials |
| NCT05580107 | MDPK67b in Patients With Prostate Cancer | unknown | Phase 1 | 15 | Med Discovery SAINDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04404140 | A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). | terminated | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 4 | Oct 17, 2023 | clinicaltrials |
| NCT04045613 | Derazantinib and Atezolizumab in Patients With Urothelial Cancer(FIDES-02) | completed | Phase 1 / Phase 2 | 95 | Basilea PharmaceuticaINDUSTRY | 14 | Oct 13, 2023 | clinicaltrials |
| NCT03188965 | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 | 229 | BayerINDUSTRY | 7 | Oct 11, 2023 | clinicaltrials |
| NCT04443010 | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma(GLIOSUN) | recruiting | Phase 1 / Phase 2 | 226 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT00292045 | Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer | completed | Phase 1 | 15 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 4, 2023 | clinicaltrials |
| NCT02193503 | MVX-ONCO-1 in Patients With Solid Tumor | active not recruiting | Phase 1 | 34 | Maxivax SAINDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03030612 | A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 38 | OncoVerity, Inc.INDUSTRY | 2 | Aug 9, 2023 | clinicaltrials |
| NCT03745989 | Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) | completed | Phase 1 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Jul 27, 2023 | clinicaltrials |
| NCT02592707 | Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs | terminated | Phase 1 / Phase 2 | 40 | IpsenINDUSTRY | 8 | Jul 19, 2023 | clinicaltrials |
| NCT03779230 | Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse(GLIOMOON) | completed | Phase 1 / Phase 2 | 20 | Philogen S.p.A.INDUSTRY | 1 | Jun 29, 2023 | clinicaltrials |
| NCT03236857 | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | completed | Phase 1 | 143 | AbbVieINDUSTRY | 8 | May 22, 2023 | clinicaltrials |
| NCT02895360 | Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 43 | Basilea PharmaceuticaINDUSTRY | 1 | May 10, 2023 | clinicaltrials |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | terminated | Phase 1 | 97 | MEI Pharma, Inc.INDUSTRY | 2 | May 9, 2023 | clinicaltrials |
| NCT02371447 | VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 39 | Swiss Cancer InstituteOTHER | 2 | Apr 13, 2023 | clinicaltrials |
| NCT01164891 | A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma | completed | Phase 1 | 7 | Hoffmann-La RocheINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT01040026 | Expanded Natural Killer (NK) Cells for Multiple Myeloma Study | completed | Phase 1 / Phase 2 | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT02598960 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. | completed | Phase 1 / Phase 2 | 295 | Bristol-Myers SquibbINDUSTRY | 10 | Mar 6, 2023 | clinicaltrials |
| NCT03251924 | A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 80 | Bristol-Myers SquibbINDUSTRY | 4 | Feb 28, 2023 | clinicaltrials |
| NCT01714739 | A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 337 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 2, 2023 | clinicaltrials |
| NCT02910843 | Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer(RECAP) | terminated | Phase 1 | 25 | Swiss Cancer InstituteOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT02607813 | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations | terminated | Phase 1 | 142 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 21, 2022 | clinicaltrials |
| NCT05572463 | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Nov 18, 2022 | clinicaltrials |
| NCT00199797 | Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 20 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 10, 2022 | clinicaltrials |
| NCT02431559 | Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 53 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 10, 2022 | clinicaltrials |
| NCT04496999 | HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.(HDMM) | terminated | Phase 1 | 2 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03524898 | NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma | terminated | Phase 1 / Phase 2 | 39 | Swiss Cancer InstituteOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT00819221 | AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours | terminated | Phase 1 | 44 | AstraZenecaINDUSTRY | 2 | Aug 30, 2022 | clinicaltrials |
| NCT04261075 | IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. | completed | Phase 1 | 57 | MedImmune LLCINDUSTRY | 4 | Aug 15, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT05468294 | F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer(Nivokin) | unknown | Phase 1 / Phase 2 | 3 | Philogen S.p.A.INDUSTRY | 1 | Jul 21, 2022 | clinicaltrials |
| NCT01555281 | Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma | terminated | Phase 1 / Phase 2 | 33 | Swiss Cancer InstituteOTHER | 2 | Jul 7, 2022 | clinicaltrials |
| NCT03102320 | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors(ARCS-Multi) | completed | Phase 1 | 173 | BayerINDUSTRY | 12 | Jun 30, 2022 | clinicaltrials |
| NCT03245450 | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Eisai Inc.INDUSTRY | 8 | Jun 28, 2022 | clinicaltrials |
| NCT04632316 | A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 33 | Glycostem Therapeutics BVINDUSTRY | 5 | Jun 21, 2022 | clinicaltrials |
| NCT02877550 | Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients | completed | Phase 1 | 25 | Swiss Cancer InstituteOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT01884922 | Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults(VINILO) | completed | Phase 1 | 35 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 8 | May 27, 2022 | clinicaltrials |
| NCT03172936 | Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | terminated | Phase 1 | 106 | Novartis PharmaceuticalsINDUSTRY | 8 | May 3, 2022 | clinicaltrials |
| NCT03886649 | Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. | terminated | Phase 1 | 7 | Swiss Cancer InstituteOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT03458117 | T-VEC in Non-melanoma Skin Cancer(20139157 T-VEC) | completed | Phase 1 | 26 | University of ZurichOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT02356458 | Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | terminated | Phase 1 / Phase 2 | 58 | Swiss Cancer InstituteOTHER | 3 | Mar 11, 2022 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials